Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from GoodRx

Wegovy works. But here's what happens if you can't afford to keep taking the drug

The new weight-loss drugs can be life-changing for people facing health conditions worsened by obesity, but price and spotty insurance coverage may keep them out of reach.

WEKU

Climate change magnifies health impacts of wildfire smoke in care deserts

DRESSLERVILLE, Nev. — Smoke began billowing into the skies of northwestern Nevada in September, clouding the mountains, dimming the sun — and quashing residents’ hopes that they would be spared from wildfires and the awful air quality the blazes produce.

Tribune News Service

5 things to know about the FDA's flawed approach to accelerated drug approvals

An NPR investigation found stalled confirmatory trials and lax enforcement are plaguing the FDA's accelerated approval of drugs for urgent medical needs.

WEKU

From analysis to the latest developments in health,
read the most diverse news in one place.

Drugmakers are slow to prove medicines that got a fast track to market really work

Stalled confirmatory trials and lax enforcement plague the Food and Drug Administration's accelerated approval pathway for pharmaceuticals that target urgent medical needs.

WEKU

Baird Maintains Neutral Rating for GoodRx Holdings: Here's What You Need To Know

Baird has decided to maintain its Neutral rating of GoodRx Holdings (NASDAQ:GDRX) and lower its price target from $7.00 to $6.00. Shares of GoodRx Holdings are trading up 6.94% over the last 24 hours, at $6.32 per share. A move to $6.00 would account for a 5.06% decline from the…

Benzinga

Goldman Sachs Maintains Buy Rating for GoodRx Holdings: Here's What You Need To Know

Goldman Sachs has decided to maintain its Buy rating of GoodRx Holdings (NASDAQ:GDRX) and lower its price target from $30.00 to $12.00. Shares of GoodRx Holdings are trading up 1.32% over the last 24 hours, at $8.07 per share.

Benzinga

GoodRx Shares Tumble As FY22 Guidance Hit By Grocery Chain Prescription Dispute

GoodRx Holdings Inc (NASDAQ: GDRX) shares fell after it expects FY22 revenue to take a hit due to recent actions by one grocery store chain that represents a sizable chunk of its grocery prescription business.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Can billionaire celebrity Mark Cuban fix America’s broken health system?

The celebrity investor has teamed up with a soft-spoken radiologist to tackle the USA’s healthcare crisis – and he has drug industry middlemen squarely in his sights, reports Io Dodds

The Independent UK

¿Enfrentando la inflación? Expertos ofrecen consejos conforme a la edad

Un día de este mes, Olivia Jurkovich pagó 53 dólares por llenar parcialmente su tanque de gasolina. Eso es 20 dólares más de lo que normalmente paga para llenar su Mazda SUV.

Tribune News Service

Trying to fight inflation? Experts offer age-based tips

Olivia Jurkovich paid $53 for a partial tank of gas one day this month. That's $20 more than what she normally pays to top off her Mazda SUV.

Tribune News Service

3 Healthtech Stocks Wall Street Predicts Will Rally More Than 40% or More: GoodRx, 23andMe, and Exact Sciences

The COVID-19 pandemic has accelerated digital adoption in healthcare. And because this trend is attracting massive investments into digital health care, Wall Street analysts expect popular health tech stocks Exact Sciences Corp (EXAS), GoodRx Holdings (GDRX), 23andMe (ME) to rally in price soon. Read on.

StockNews.com

TherapeuticsMD Shares Soars After VitaCare Divestiture In $150M Deal

TherapeuticsMD Inc (NASDAQ:TXMD) has agreed to divest its VitaCare Prescription Services business to GoodRx Holdings Inc (NASDAQ:GDRX) for $150 million. VitaCare is a consumer-focused digital healthcare platform. TherapeuticsMD will also receive an additional $7 million in cash consideration contingent upon vitaCare's financial performance through 2023. TXMD will also enter into a long-term services agreement to…

Benzinga

GoodRx Plunges As Q4 Fall Short Of Expectations, Analysts Cut Price Target

Consumer-focused digital healthcare, GoodRx Holdings Inc (NASDAQ: GDRX) shares are plunging after the company's

Benzinga

Why GoodRX Shares Are Plummeting Today

GoodRx Holdings Inc (NASDAQ: GDRX) is plunging Tuesday after the company reported worse-than-expected fourth-quarter financial results and issued guidance below estimates.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.